Moderna [MRNA] vs Insmed [INSM] Detailed Stock Comparison

Moderna Inc.

NASDAQ
Loading...

Insmed Inc.

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 19 vital metrics comparison: Moderna Inc. wins in 12 metrics, Insmed Inc. wins in 7 metrics, with 0 ties. Moderna Inc. appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Moderna Inc. Insmed Inc. Better
P/E Ratio (TTM) 24.97 -22.40 Moderna Inc.
Price-to-Book Ratio 2.47 40.88 Moderna Inc.
Debt-to-Equity Ratio 15.09 101.43 Moderna Inc.
PEG Ratio -0.91 -1.34 Moderna Inc.
EV/EBITDA -5.92 -30.30 Moderna Inc.
Profit Margin (TTM) -145.16% -210.54% Moderna Inc.
Operating Margin (TTM) -126.40% -94.64% Insmed Inc.
Return on Equity -28.87% -249.28% Moderna Inc.
Return on Assets (TTM) -14.51% -28.99% Moderna Inc.
Free Cash Flow (TTM) $-2.08B $-967.58M Insmed Inc.
1-Year Return 77.67% 53.32% Moderna Inc.
Price-to-Sales Ratio (TTM) 11.06 50.18 Moderna Inc.
Enterprise Value $16.92B $29.71B Insmed Inc.
EV/Revenue Ratio 8.71 48.99 Moderna Inc.
Gross Profit Margin (TTM) 33.14% 83.24% Insmed Inc.
Revenue per Share (TTM) $5 $3 Moderna Inc.
Earnings per Share (Diluted) $-7.26 $-6.35 Insmed Inc.
Beta (Stock Volatility) 1.34 1.10 Insmed Inc.
Short % of Float 18.71% 7.19% Insmed Inc.

Moderna Inc. vs Insmed Inc. Stock Performance Analysis

Loading Price Chart...

MRNA
INSM

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Moderna Inc.7.49%3.05%3.72%-1.55%94.84%58.98%
Insmed Inc.0.13%-2.39%-25.82%-29.35%-49.77%-41.36%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Moderna Inc.77.67%-63.84%-77.10%153.71%153.71%153.71%
Insmed Inc.53.32%447.13%322.07%796.14%920.13%585.32%

Performance & Financial Health Analysis: Moderna Inc. vs Insmed Inc.

MetricMRNAINSM
Market Information
Market Cap i$20.96B$31.05B
Market Cap CategoryLarge capLarge cap
10 Day Avg. Volume i6,250,5021,921,156
90 Day Avg. Volume i6,358,6142,308,299
Last Close$49.06$103.86
52 Week Range$22.28 - $59.55$70.57 - $212.75
% from 52W High-17.62%-51.18%
All-Time High$497.49 (Aug 09, 2021)$212.81 (Dec 02, 2025)
% from All-Time High-90.14%-51.20%
Growth Metrics
Quarterly Revenue Growth-0.30%1.53%
Quarterly Earnings Growth-0.29%1.53%
Financial Health
Profit Margin (TTM) i-1.45%-2.11%
Operating Margin (TTM) i-1.26%-0.95%
Return on Equity (TTM) i-0.29%-2.49%
Debt to Equity (MRQ) i15.09101.43
Cash & Liquidity
Book Value per Share (MRQ)$21.95$3.45
Cash per Share (MRQ)$14.68$6.63
Operating Cash Flow (TTM) i$-1,872,999,936$-935,014,016
Levered Free Cash Flow (TTM) i$-1,326,499,968$-534,054,880
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/AN/A

Valuation & Enterprise Metrics Analysis: Moderna Inc. vs Insmed Inc.

MetricMRNA (Apr 24, 2026)INSM (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) i24.97-22.40
Forward P/E i-11.75188.19
PEG Ratio i-0.91-1.34
Price to Sales (TTM) i11.0650.18
Price to Book (MRQ) i2.4740.88
Market Capitalization
Market Capitalization i$20.96B$31.05B
Enterprise Value i$16.92B$29.71B
Enterprise Value Metrics
Enterprise to Revenue i8.7148.99
Enterprise to EBITDA i-5.92-30.30
Risk & Other Metrics
Beta i1.341.10
Book Value per Share (MRQ) i$21.95$3.45

Financial Statements Comparison: Moderna Inc. vs Insmed Inc.

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricMRNA (2025)INSM (2025)
Revenue/Sales i1.92B606.42M
Cost of Goods Sold i868.00M122.94M
COGS % of Revenue i45.2%20.3%
Gross Profit i1.05B483.49M
Gross Margin i54.8%79.7%
Research & Development i3.13B771.09M
Operating Income (EBIT) i-3.07B-994.78M
Operating Margin i-159.9%-164.0%
EBITDA i-2.54B-986.38M
EBITDA Margin i-132.0%-162.7%
Pre-Tax Income i-2.77B-1.27B
Pre-Tax Income % of Revenue i-144.0%-209.7%
Income Tax i54.00M5.03M
Income Tax % of Revenue i2.8%0.8%
Net Income (Profit) i-2.82B-1.28B
Profit Margin i-146.8%-210.5%

Balance Sheet & Liquidity Metrics

MetricMRNA (2025)INSM (2025)
Cash & Equivalents i2.60B510.45M
Total Current Assets i6.54B1.79B
Total Current Assets % of Revenue i340.5%295.9%
Total Current Liabilities i1.99B468.87M
Total Current Liabilities % of Revenue i103.4%77.3%
Long-Term Debt i1.26B573.86M
Long-Term Debt % of Revenue i65.7%94.6%
Total Shareholders Equity i8.65B738.98M
Retained Earnings i7.22B-5.64B
Retained Earnings % of Revenue i375.8%-929.5%
Property, Plant & Equipment i1.39B76.73M

Cash Flow Statement Comparison

MetricMRNA (2025)INSM (2025)
Operating Cash Flow i-1.97B-943.31M
Operating Cash Flow % of Revenue i-102.2%-155.6%
Capital Expenditures i-192.00M-32.56M
Free Cash Flow i-2.08B-967.58M
FCF Margin i-108.0%-159.6%
Debt Repayment i-22.00M-4.93M
Common Stock Repurchase iN/AN/A

Short Interest & Institutional Ownership Analysis

MetricMRNAINSM
Shares Short i60.65M13.76M
Short Ratio i7.115.69
Short % of Float i18.71%7.19%
Shares Outstanding i394.00M214.26M
Float Shares i368.43M193.23M
% Held by Insiders i7.32%0.55%
% Held by Institutions i77.05%102.57%
% Held by Public i15.63%-3.12%

Dividend Analysis & Yield Comparison: Moderna Inc. vs Insmed Inc.

MetricMRNAINSM
Last 12-Month Dividend iN/AN/A
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/AN/A
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/AN/A
Ex-Dividend DateN/AN/A